Satralizumab

Category: Immunosuppressive



Satralizumab Overview

Satralizumab, sold under the brand name Enspryng, is a humanized monoclonal antibody medication that is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease.[2][3] The drug is being developed by Chugai Pharmaceutical, a subsidiary of Roche.[4] Satralizumab regulates inflammation by inhibiting the interleukin-6 (IL-6) receptor, a key mediator of the immune response.[5] The most common...

Read more Satralizumab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Satralizumab

Recent Satralizumab Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Satralizumab
  • Injection: 120mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Satralizumab or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 26 October 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA